Longitudinal trajectories in treated and untreated schizophrenia
Longitudinal trajectories in treated and untreated schizophrenia
批准号:
10306962
负责人:
MATCHERI S. KESHAVAN
金额:
$64.17万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-16 至 2026-07-31
关键词:
AdultAffectAgeAntipsychotic AgentsBrainCharacteristicsChinaChronicChronologyClinicalCognitionCognitiveConsensusCross-Sectional StudiesEducationEthicsEthnic OriginFamilyFutureGenderGoalsHealth PrioritiesImageImpaired cognitionIndividualInterventionKnowledgeLongitudinal StudiesMachine LearningMagnetic Resonance ImagingMeasuresMedicalMental HealthMethodsNatureNerve DegenerationNeurobiologyNeurocognitive DeficitPathway interactionsPatientsPharmaceutical PreparationsProcessProvincePsychopathologyPsychosesResearchResearch PersonnelResourcesRiskRural CommunitySamplingSchizophreniaScientific Advances and AccomplishmentsScoring MethodSelection BiasSignal TransductionSourceSpecific qualifier valueTimeTrainingbasecareercognitive abilitycognitive performancecohortcomorbiditycomparison groupfollow-uphuman old age (65+)insightlow and middle-income countriesprogramsrecruitrural areascale upsecondary analysissocialtreatment responseuptake
中文摘要
对未经治疗的非情感性精神病病程的研究在很大程度上局限于城市样本
英文摘要
Studies of the untreated course of non-affective psychosis have been largely limited to urban samples with
short duration of untreated psychosis (DUP) (less than 5 years). We propose to take advantage of a unique,
time-limited opportunity to study the extended untreated course of psychosis among individuals with psychosis
(IWP) with very long DUP (>30 yrs), in predominantly rural areas of China. Our first goal is to develop
knowledge about the course of untreated ongoing psychosis and associated neurobiology over a span of
decades. Our second goal is to expand knowledge about initiating treatment (e.g. antipsychotic medications) in
IWP who remain untreated into late adulthood. This R01 proposes a 3-year follow-up of 400 untreated IWP,
400 treated IWP, and 400 healthy controls (HCs) from mainly rural areas of Guangxi Province and Hunan
Province (matched on key variables). Our primary focus is on cognitive performance, but we will also compare
the 3 groups on other symptomatic and functional domains. Moreover, comparisons of prolonged untreated
IWP who accept treatment (i.e., the ‘newly-treated’) versus refuse treatment (i.e., the ‘ongoing untreated’) will
provide crucial information about the effects of initiating antipsychotic treatment in IWP with extended DUP.
Our specific aims include: Aim 1) compare change in cognitive performance from baseline to 3-year follow-up
in 3 groups: ongoing untreated IWP, matched treated IWP, and matched HCs. 1a) we hypothesize in the
primary analysis that decline in cognitive performance over 3-year follow-up, measured by the MATRICS
Consensus Cognitive Battery (MCCB), will be greatest in the ongoing untreated group, intermediate in the
matched treated group, and least in HC. 1b) a secondary analysis will similarly compare changes in specific
cognitive domains and those who show progressive cognitive declines between the 3 groups, in the same
order hypothesized in 1a). Aim 2) conduct secondary analyses to compare change in measures of
psychopathology, social and vocational functioning, medical co-morbidity, and social burden from baseline to
3- year follow-up among the same 3 groups specified in Aim 1. Aim 3) conduct secondary analyses comparing
the ongoing untreated and newly treated groups with respect to: 3a) change in cognitive performance; 3b)
change in psychopathology, functioning, medical co-morbidity, and social burden. In Aims 3a) + 3b), we
identify characteristics of newly treated IWP who remain nonresponsive to treatment. 3c) identify patient-,
family-, and other stakeholder-level factors associated with medication uptake via the 686 Program. Aim 4) via
capacity-building, we identify a cohort of new clinical researchers and provide training via this large-scale study
in guiding them towards sustainable research careers. Finally, in exploratory analyses, we will compare “brain
age gap” (i.e., an imaging measure of brain age minus chronological age) over the 3-year period in a subset of
individuals from each group. We propose to illuminate the course of cognition in a large sample of prolonged,
untreated psychosis, thus advancing understanding of psychosis in China, other LMICs, and worldwide.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS)
-
批准号:10683233
-
项目类别:
-
资助金额:$25.91万
-
财政年份:2022
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
4/5: Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (CLOZAPINE)
-
批准号:10396433
-
项目类别:
-
资助金额:$27.51万
-
财政年份:2021
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
4/5: Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (CLOZAPINE)
-
批准号:10613507
-
项目类别:
-
资助金额:$27.5万
-
财政年份:2021
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
Characterizing cognition across the lifespan in untreated psychosis in China
-
批准号:9403816
-
项目类别:
-
资助金额:$60.26万
-
财政年份:2015
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
Sleep spindles in early course schizophrenia and first-degree relatives
-
批准号:9139499
-
项目类别:
-
资助金额:$62.48万
-
财政年份:2015
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
Sleep spindles in early course schizophrenia and first-degree relatives
-
批准号:9702857
-
项目类别:
-
资助金额:$55.46万
-
财政年份:2015
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
Adaptation of Cognitive Enhancement Therapy for persons at Psychosis High Risk
-
批准号:8976169
-
项目类别:
-
资助金额:$26.1万
-
财政年份:2014
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
4/6 Psychosis and Affective Research Domains and Intermediate Phenotypes (PARDIP)
-
批准号:8506547
-
项目类别:
-
资助金额:$26.1万
-
财政年份:2013
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
4/6 Psychosis and Affective Research Domains and Intermediate Phenotypes (PARDIP)
-
批准号:8706965
-
项目类别:
-
资助金额:$26.1万
-
财政年份:2013
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
Brain Imaging, Cognitive Enhancement and Early Schizophrenia
-
批准号:8453355
-
项目类别:
-
资助金额:$60.08万
-
财政年份:2012
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
Brain Imaging, Cognitive Enhancement and Early Schizophrenia
-
批准号:8644914
-
项目类别:
-
资助金额:$60.76万
-
财政年份:2012
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
Brain Imaging, Cognitive Enhancement and Early Schizophrenia
-
批准号:8236770
-
项目类别:
-
资助金额:$67.46万
-
财政年份:2012
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
Brain Imaging, Cognitive Enhancement and Early Schizophrenia
-
批准号:8831006
-
项目类别:
-
资助金额:$60.16万
-
财政年份:2012
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
CORE--CLINICAL
-
批准号:7553455
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2007
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
4/5 Bipolar-Schizophrenia Network for Intermediate Phenotypes
-
批准号:9293368
-
项目类别:
-
资助金额:$56.47万
-
财政年份:2007
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
Bipolar & Schizophrenia Consortium for Parsing Intermediate Phenotypes
-
批准号:7668419
-
项目类别:
-
资助金额:$80.15万
-
财政年份:2007
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
Bipolar & Schizophrenia Consortium for Parsing Intermediate Phenotypes
-
批准号:7917305
-
项目类别:
-
资助金额:$77.04万
-
财政年份:2007
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
Bipolar & Schizophrenia Consortium for Parsing Intermediate Phenotypes
-
批准号:7384973
-
项目类别:
-
资助金额:$80.95万
-
财政年份:2007
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
EFFECT OF QUETIAPINE ON DELTA SLEEP DEFICITS IN SCHIZOPHRENIA
-
批准号:7201198
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2005
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
BRAIN CIRCUITRY AND COGNITION IN PSYCHOSIS
-
批准号:7201211
-
项目类别:
-
资助金额:$2.3万
-
财政年份:2005
-
负责人:MATCHERI S. KESHAVAN
-
依托单位:
海外基金